MCK 10-Q Quarterly Reports

McKesson Corporation reported strong financial performance for the period ending December 30, 2025. Total revenues saw a significant increase of 11% for the quarter and 15% for the nine-month period compared to the prior year, driven by robust growth in the North American Pharmaceutical and Oncology & Multispecialty segments. Diluted earnings per share (EPS) also showed substantial improvement, rising to $9.59 for the quarter and $24.73 for the nine months, reflecting a 38% and 57% increase, respectively. The company completed two strategic acquisitions during the period: PRISM Vision Holdings, LLC for $875 million and Community Oncology Revitalization Enterprise Ventures, LLC for $2.5 billion, both aimed at strengthening its Oncology & Multispecialty segment. These acquisitions, along with a renewed focus on operational efficiencies, are expected to contribute to future growth. McKesson also continued its capital return program, repurchasing $2.1 billion in common stock and increasing its quarterly dividend to $0.82 per share.

McKesson Corporation reported robust financial performance for the second quarter and first half of fiscal year 2026. Revenues saw a significant increase of 10% and 16% year-over-year for the respective periods, driven by strong growth in the North American Pharmaceutical and Oncology & Multispecialty segments. Diluted Earnings Per Share (EPS) surged to $8.92 in Q2 and $15.16 for the first half, up substantially from the prior year, reflecting improved profitability. The company completed two significant acquisitions during the period, PRISM Vision Holdings, LLC and Community Oncology Revitalization Enterprise Ventures, LLC, further expanding its healthcare services capabilities. Despite increased investments in acquisitions and ongoing restructuring initiatives, McKesson demonstrated effective cost management, with total operating expenses decreasing by 20% and 9% for the quarter and half-year, respectively. The company also returned significant capital to shareholders through share repurchases ($1.4 billion in the first half) and a dividend increase. While facing some operational challenges, such as a provision for bad debts related to Rite Aid's bankruptcy, McKesson's strategic acquisitions and solid operational execution position it for continued growth and value creation for its investors.

McKesson Corporation reported strong revenue growth of 23% for the second quarter of fiscal year 2025, reaching $97.8 billion, primarily driven by its U.S. Pharmaceutical segment. Despite this top-line expansion, net income attributable to McKesson Corporation saw a decrease of 14% to $784 million, resulting in diluted earnings per share of $6.25, down from $7.00 in the prior year period. This decline is partly attributed to a $189 million provision for bad debts related to the Rite Aid bankruptcy and increased operating expenses associated with recent significant acquisitions. The company completed two major acquisitions during the quarter: PRISM Vision Holdings, LLC for $874 million and Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for $2.5 billion. These acquisitions, along with increased investments in technology, contributed to a rise in operating expenses and a significant use of cash in investing activities. McKesson also returned $671 million to shareholders through share repurchases and dividends, and announced an increase in its quarterly dividend to $0.82 per share.

McKesson Corporation reported strong revenue growth for the third quarter and first nine months of fiscal year 2025, driven by its U.S. Pharmaceutical segment and increased volumes in its International segment. Diluted Earnings Per Share (EPS) saw a significant increase in the third quarter, though it slightly declined year-over-year for the nine-month period. The company also completed the divestiture of its Canadian retail businesses. Significant charges related to restructuring initiatives and remeasuring the Canadian retail disposal group to fair value were incurred. McKesson continues to manage its substantial opioid-related litigation liabilities, with significant payments made and a large accrued liability remaining. The company's financial position remains solid, supported by robust operating cash flow and access to credit facilities. McKesson continues to return capital to shareholders through dividends and substantial share repurchases, with a significant remaining authorization. Strategic acquisitions, including a controlling interest in PRISM Vision Holdings, are underway to further enhance its business segments. Investors should monitor ongoing litigation developments, particularly those related to opioids, and the integration of new acquisitions.

McKesson Corporation reported its financial results for the second quarter and first half of fiscal year 2025. Total revenues saw a significant increase of 21% for the quarter and 14% for the six-month period, driven by growth in the U.S. Pharmaceutical segment and increased pharmaceutical distribution volumes internationally. However, diluted earnings per share decreased substantially, reflecting higher operating expenses and specific charges. Key items impacting the results include a substantial charge of $643 million related to the remeasurement of the Canadian retail disposal group to fair value less costs to sell. Additionally, the company incurred $227 million in restructuring charges for enterprise-wide technology modernization initiatives. The company also continues to manage its significant estimated liability for opioid-related claims, totaling $6.4 billion as of period end. Despite the earnings decline, McKesson demonstrated strong operational cash flow and continued to return capital to shareholders through share repurchases ($2.0 billion in the first half) and a raised quarterly dividend. The company also announced a significant acquisition in the oncology sector, pending regulatory approval.

McKesson Corporation reported total revenues of $79.3 billion for the fiscal second quarter ended June 30, 2024, a 6% increase compared to the prior year. This growth was primarily driven by its U.S. Pharmaceutical segment, benefiting from market growth in specialty pharmaceuticals and higher volumes. Despite revenue growth, net income attributable to McKesson Corporation saw a slight decrease to $915 million, or $7.00 per diluted share, down from $958 million, or $7.02 per diluted share, in the same period last year. This decline was influenced by increased operating expenses, particularly higher claims and litigation charges related to opioid settlements, and a decrease in gross profit margin. The company repurchased $528 million of its common stock and paid $82 million in dividends during the quarter, underscoring its commitment to returning capital to shareholders, with an additional $4.0 billion authorization for share repurchases approved in July 2024.

McKesson Corporation reported an increase in revenues for the third quarter and first nine months of fiscal year 2024, driven by strong performance in its U.S. Pharmaceutical segment, particularly in specialty pharmaceuticals and retail national accounts. Despite revenue growth, gross profit saw a slight decrease due to the impact of the European divestiture and increased operating expenses. Diluted earnings per share from continuing operations experienced a significant decline year-over-year, largely influenced by a substantial provision for bad debts related to the bankruptcy of its customer, Rite Aid. The company's financial position remains solid, with active capital allocation strategies including significant share repurchases and dividend payments. McKesson is managing its debt effectively and has a substantial remaining authorization for stock buybacks. However, investors should note the ongoing legal proceedings, particularly those related to opioid litigation, which represent a significant contingent liability. The company continues to navigate these challenges while focusing on operational efficiencies and strategic growth.

McKesson Corporation reported strong revenue growth for the first six months of fiscal year 2024, with revenues increasing by 10% to $151.7 billion compared to the prior year period. This growth was primarily driven by the U.S. Pharmaceutical segment, which saw higher volumes and price increases, as well as growth in the Prescription Technology Solutions segment. However, net income attributable to McKesson Corporation decreased by 4% to $1.62 billion for the six-month period, resulting in diluted earnings per share of $11.95, a slight increase from $11.68 in the prior year. The decrease in net income was impacted by a significant provision for bad debts related to Rite Aid's bankruptcy and a notable discrete tax benefit in the prior year. The company continues to manage substantial opioid-related litigation liabilities, with an accrued liability of $6.6 billion as of September 30, 2023. McKesson demonstrated a commitment to returning capital to shareholders, repurchasing $1.5 billion in common stock and paying $149 million in dividends during the first six months of fiscal year 2024. The company also increased its quarterly dividend and maintained a substantial remaining authorization for share repurchases, signaling confidence in its ongoing financial health and future prospects.

McKesson Corporation (MCK) reported strong revenue growth of 11% year-over-year for the quarter ending June 29, 2023, reaching $74.5 billion. This increase was primarily driven by robust performance in the U.S. Pharmaceutical segment, benefiting from market growth, higher volumes, and specialty pharmaceutical expansion. Despite flat gross profit, operating expenses saw a 3% decrease, contributing to a significant 24% rise in income from continuing operations to $997 million. Diluted earnings per share (EPS) from continuing operations also saw a substantial increase, growing by 34% to $7.02. The company demonstrated effective capital management, returning $770 million to shareholders through $696 million in stock repurchases and $74 million in dividends. Management also announced an increase in the quarterly dividend and a significant expansion of its share repurchase authorization, signaling confidence in future financial performance. While the company faces ongoing litigation, particularly related to opioid claims, the overall financial health appears solid, supported by consistent revenue generation and disciplined expense management.

McKesson Corporation's third quarter of fiscal year 2023 (ending December 30, 2022) showed robust revenue growth of 3% year-over-year, reaching $70.49 billion. This top-line performance was primarily driven by strong market growth in the U.S. Pharmaceutical segment, fueled by increased drug utilization, new product launches, and price adjustments. However, gross profit saw a 7% decrease due to a higher mix of lower-margin business, particularly from the divested International segment and unfavorable foreign currency impacts. The company made significant strategic moves, including the acquisition of Rx Savings Solutions for $600 million (plus contingent consideration) to bolster its Prescription Technology Solutions segment, and the formation of an oncology research business with HCA Healthcare. Simultaneously, McKesson continued its strategic divestitures by completing the sale of its European Union disposal group. These actions underscore McKesson's focus on optimizing its portfolio and strengthening its core businesses. Despite revenue growth, the company's net income attributable to McKesson Corporation experienced a substantial increase to $1.08 billion from a loss of $7 million in the prior year period, largely due to significant favorable adjustments related to prior year European divestiture charges and a lower share count from active share repurchase programs.

McKesson Corporation's Q2 fiscal year 2023 (ended September 29, 2022) report shows a significant increase in revenue, primarily driven by growth in its U.S. Pharmaceutical segment, which benefited from market expansion, higher drug utilization, and new product launches. Despite revenue growth, gross profit saw a slight decrease due to factors including divestitures in the International segment and foreign currency fluctuations. The company also reported a substantial increase in diluted earnings per common share from continuing operations, attributed to favorable adjustments from the remeasurement of its EU disposal group and a lower share count resulting from ongoing share repurchases. The company's strategic initiatives, including recent acquisitions like Rx Savings Solutions and the formation of an oncology research business, along with the completion of its EU divestiture, are shaping its future. McKesson continues to prioritize returning capital to shareholders through significant share repurchases and dividend payments, demonstrating a commitment to shareholder value while managing its substantial opioid-related litigation liabilities.

McKesson Corporation reported strong financial results for the first quarter of fiscal year 2023, ending June 30, 2022. Revenues saw a notable increase of 7% year-over-year, reaching $67.2 billion, driven primarily by market growth in the U.S. Pharmaceutical segment. Despite a flat gross profit, the company successfully reduced total operating expenses by 19%, leading to a significant 79% increase in income from continuing operations before income taxes. The company also demonstrated a strong commitment to returning capital to shareholders, repurchasing $1.0 billion in common stock and raising its quarterly dividend. Diluted earnings per share from continuing operations surged by 70% to $5.25, bolstered by reduced corporate expenses, growth in North American businesses, and a lower share count resulting from ongoing share repurchase programs. McKesson continues to navigate evolving market conditions, including the lingering impacts of COVID-19 and global economic factors, while maintaining a robust liquidity position.

McKesson Corporation's (MCK) third-quarter fiscal year 2022 results (ending December 30, 2021) show a return to profitability after a significant loss in the prior year period, driven by revenue growth across its segments. Total revenues increased by 10% year-over-year, reflecting strong performance in the U.S. Pharmaceutical segment and recovery from pandemic-related impacts. The company's net income attributable to McKesson Corporation swung from a substantial loss to a profit, though diluted EPS from continuing operations was slightly negative due to specific charges. Significant factors influencing the quarter include the ongoing divestiture of European businesses, which resulted in substantial remeasurement charges impacting operating expenses, and continued progress in settling opioid-related litigation, with an estimated liability of $8.2 billion. Despite these complexities, McKesson demonstrated robust operational execution and a strong recovery trajectory.

McKesson Corporation reported increased revenues for the second quarter and first half of fiscal year 2022, driven by market growth in its U.S. Pharmaceutical segment and contributions from COVID-19 related programs. Gross profit also saw a significant increase, benefiting from vaccine and ancillary supply kit distribution, as well as a recovery from pandemic-related impacts. However, the company recorded substantial charges related to its European business divestiture and ongoing opioid litigation, which impacted net income. The company continued its share repurchase program and increased its quarterly dividend.

McKesson Corporation reported a strong fiscal first quarter for 2022, with revenues increasing 13% year-over-year to $62.7 billion. This growth was primarily driven by market expansion within its U.S. Pharmaceutical segment and a recovery in pharmaceutical distribution volumes post-COVID-19. Net income attributable to McKesson Corporation rose by 9% to $486 million, resulting in diluted earnings per share of $3.07, up 13% from the prior year. The company also returned significant capital to shareholders through $1 billion in share repurchases and a dividend increase announcement. Despite facing ongoing litigation, including substantial opioid-related charges, McKesson demonstrated operational resilience and strategic execution, including progress on the planned sale of its European businesses.

McKesson Corporation's Form 10-Q filing for the period ending December 30, 2020, reveals a significant net loss attributable to McKesson Corporation of $6.226 billion, or $39.03 per diluted share. This substantial loss is largely driven by a substantial charge of $8.1 billion related to estimated opioid-related litigation liabilities. Despite this significant charge, the company's revenue for the quarter increased by 6% year-over-year to $62.6 billion, and for the nine-month period by 4% to $179.1 billion, primarily due to growth in the U.S. Pharmaceutical segment and increased demand for COVID-19 tests and PPE in the Medical-Surgical Solutions segment. The company also reported changes in its segment reporting structure and continues to navigate the impacts of the COVID-19 pandemic, including its role as a distributor for COVID-19 vaccines and related supplies. While revenue growth is present, the significant litigation charge heavily impacts profitability. Investors should monitor the ongoing resolution of the opioid litigation and its ultimate financial impact, as well as the company's performance across its evolving business segments.

McKesson Corporation's (MCK) Form 10-Q filing for the period ending September 29, 2020, demonstrates a notable rebound in financial performance compared to the prior year's third quarter. The company reported a significant increase in net income attributable to McKesson Corporation, rising to $577 million from a loss of $730 million in the same period last year. This turnaround was driven by a 6% increase in total revenues, reaching $60.8 billion, primarily fueled by growth in the U.S. Pharmaceutical segment and a recovery in distribution volumes that had been impacted by the early stages of the COVID-19 pandemic. The company is actively managing its operational efficiency through various restructuring initiatives, which contributed to the reported restructuring, impairment, and related charges. Despite these ongoing efforts and the broader economic uncertainties stemming from COVID-19, McKesson has shown resilience. The company also highlighted its expanded role in distributing COVID-19 vaccines and ancillary supplies, positioning it to play a critical part in the ongoing public health response. Investors will likely focus on the company's ability to maintain revenue growth, manage costs effectively amidst ongoing pandemic-related disruptions, and navigate the significant legal and regulatory challenges, particularly the opioid litigation.

McKesson Corporation's (MCK) fiscal first quarter of 2021 (ending June 30, 2020) showed resilience with revenues holding steady year-over-year at $55.7 billion. This stability was achieved despite the initial impacts of the COVID-19 pandemic, which led to decreased pharmaceutical distribution volumes in certain segments. However, market growth in the U.S. Pharmaceutical and Specialty Solutions segment largely offset these declines. While gross profit saw a slight decrease due to COVID-19 related disruptions like doctor's office closures and deferred procedures, the company managed operating expenses effectively, partly due to travel restrictions and a significant insurance settlement related to a shareholder derivative action. Net income attributable to McKesson Corporation increased by 5% to $444 million, resulting in diluted earnings per share of $2.72, up 21% from the prior year, benefiting from a lower share count post-spin-off of its Change Healthcare investment. The company also continued its commitment to shareholder returns by raising its quarterly dividend.

McKesson Corporation reported solid revenue growth for the third quarter and the first nine months of fiscal year 2020, driven by market expansion and increased drug utilization. However, the company experienced a significant decline in net income attributable to McKesson Corporation, largely due to a substantial impairment charge related to its investment in Change Healthcare Joint Venture. Despite this, the company's core operations in U.S. Pharmaceutical and Specialty Solutions showed improved operating profit. Investors should note the ongoing litigation and investigations, particularly concerning opioid distribution, which present a significant contingent liability. The company also announced a planned tax-efficient exit from its Change Healthcare investment.

McKesson Corporation's Q2 FY2020 (ended September 29, 2019) report shows a significant net loss of $730 million, or $3.99 per diluted share, primarily driven by a substantial non-cash impairment charge of $1,157 million related to its investment in Change Healthcare JV. While revenues saw a healthy 9% year-over-year increase to $57.6 billion, driven by market growth and expanded business with existing customers, the company's profitability was heavily impacted by this single, albeit non-cash, item. Excluding this impairment, the operational performance appears more stable, with revenue growth and controlled operating expenses as a percentage of revenue. Despite the net loss, the company's core U.S. Pharmaceutical and Specialty Solutions segment showed a 10% revenue increase and a 5% rise in operating profit, demonstrating resilience. However, the European Pharmaceutical Solutions segment experienced a slight revenue decline and reduced operating profit, impacted by store closures and foreign currency fluctuations. The company continues its strategic initiatives, including cost optimization and workforce adjustments, and has a strong liquidity position, with sufficient cash generated from operations and access to credit facilities to meet its obligations. Investors should monitor the resolution of opioid-related litigation, which remains a significant contingent liability, and the company's ongoing strategy for its Change Healthcare investment.

McKesson Corporation's (MCK) Form 10-Q for the quarter ending June 29, 2019, reveals a significant turnaround in profitability compared to the previous year. The company reported a net income attributable to McKesson Corporation of $423 million, a substantial improvement from a net loss of $138 million in the same period of 2018. This rebound was driven by strong revenue growth, increasing 6% to $55.7 billion, and a notable reduction in operating expenses, largely due to the absence of a substantial goodwill impairment charge that impacted the prior year's results. The company's financial health shows positive signs with improved earnings per share (EPS) for continuing operations, reaching $2.27 compared to a loss of $0.69 in the prior year. While the company is navigating ongoing legal and regulatory challenges, particularly concerning opioid litigation, the current financial performance indicates a solid operational recovery and a positive outlook for the near term. Investors should monitor the resolution of these legal matters and the company's ability to maintain its revenue growth and cost management strategies.

McKesson Corporation's 10-Q filing for the period ending December 30, 2018, indicates a mixed financial performance. While revenues saw an increase of 5% year-over-year for the quarter to $56.2 billion, driven by market growth and acquisitions, net income attributable to McKesson Corporation declined significantly by 48% to $469 million. This decline was largely due to substantial goodwill impairment charges, particularly in the European Pharmaceutical Solutions segment, and increased restructuring and asset impairment charges. The company also incurred significant opioid-related litigation expenses. Despite these challenges, McKesson continues to execute its strategic growth initiatives and returned capital to shareholders through dividends and share repurchases. The company anticipates that its available cash, credit facilities, and commercial paper program will be sufficient to meet its financial obligations. Investors should closely monitor the ongoing litigation regarding controlled substance distribution and the impact of regulatory changes on the company's profitability.

McKesson Corporation's Form 10-Q for the period ending September 29, 2018, reveals a modest increase in revenue for both the quarter and year-to-date periods, driven by market growth, acquisitions, and new product launches, though partially offset by customer losses and challenges in certain European markets. The company's net income attributable to McKesson Corporation saw a significant increase, largely due to a substantial one-time credit from the renegotiation of a tax receivable agreement and a decrease in goodwill impairment charges compared to the prior year's comparable period. Operationally, the company is navigating a complex environment, including ongoing opioid litigation and government reimbursement changes, particularly in the UK. Significant goodwill impairment charges were recognized in prior periods, but the current quarter shows a substantial reduction in these charges, contributing to improved profitability. The company continues to execute strategic initiatives, including restructuring to optimize its operating model and cost structure, with expected charges to be incurred throughout 2019.

McKesson Corporation reported a net loss of $138 million, or a loss of $0.68 per share, for the first quarter of fiscal year 2019, a significant decrease compared to a net income of $309 million, or $1.45 per share, in the prior year's same quarter. This decline was largely driven by a substantial $570 million goodwill impairment charge, primarily within its European Pharmaceutical Solutions segment, stemming from updated UK government reimbursement reductions and a segment reporting structure change. Additionally, restructuring and asset impairment charges of $96 million also impacted profitability. Despite the net loss, the company saw a 3% increase in total revenues, reaching $52.6 billion, driven by growth in its U.S. Pharmaceutical and Specialty Solutions segment, along with contributions from recent acquisitions. The company's gross profit margin also improved to 5.28% from 5.01% year-over-year. McKesson continues to execute its strategic initiatives, including a multi-year growth plan and ongoing share repurchases, signaling a focus on operational optimization and shareholder returns amidst ongoing market challenges.

McKesson Corporation reported a significant increase in revenue for the third quarter of fiscal year 2018, reaching $53.6 billion, up 7% year-over-year. This growth was primarily driven by its Distribution Solutions segment, particularly in North America, benefiting from market growth and strategic acquisitions. Despite revenue gains, net income attributable to McKesson Corporation saw a decrease of 18% for the first nine months of the year, totaling $1.21 billion, down from $1.48 billion in the prior year period. This decline was influenced by a substantial goodwill impairment charge of $350 million related to its European operations, restructuring and asset impairment charges in the UK, and increased operating expenses from acquisitions and business integration efforts. The company also reported a loss from its equity method investment in Change Healthcare, impacting profitability. Financially, McKesson maintained a solid liquidity position with $2.6 billion in cash and cash equivalents. The company continued its share repurchase program, demonstrating a commitment to returning capital to shareholders. However, investors should note the impact of significant non-cash charges related to goodwill impairment and restructuring, particularly in its European segment, which weigh on profitability. The company's outlook is subject to risks including changes in the healthcare industry, regulatory environments, and operational challenges in international markets.

McKesson Corporation's (MCK) third quarter of fiscal year 2018 filing (ending September 29, 2017) reveals a significant year-over-year decline in net income attributable to McKesson Corporation, falling from $307 million to $1 million. This steep decrease is largely driven by substantial goodwill impairment charges, particularly impacting the McKesson Europe segment, and restructuring/asset impairment charges related to its UK retail business. While revenues saw a modest 4% increase to $52.1 billion, driven by the Distribution Solutions segment, profitability was severely impacted by these one-time charges and a significant loss from the equity method investment in Change Healthcare. Despite the earnings hit, McKesson continued to execute on its strategic priorities, including business acquisitions and share repurchases. The company's liquidity remains strong, supported by operating cash flow and existing credit facilities. However, investors should closely monitor the ongoing legal and regulatory proceedings, especially those related to the distribution of controlled substances and opioid litigation, which could pose material risks to future financial performance.

McKesson Corporation's Q1 2018 (ended June 30, 2017) results show a significant year-over-year decline in net income attributable to McKesson Corporation, falling by 43% to $309 million, with diluted earnings per share down 39% to $1.45. This was primarily driven by a substantial decrease in income from continuing operations, impacted by lower gross profit and a newly recognized loss from the equity method investment in Change Healthcare. While overall revenues saw a modest 3% increase to $51.1 billion, largely due to growth in the Distribution Solutions segment, the Technology Solutions segment experienced an 83% revenue decline due to the deconsolidation of its core businesses. The company continued its strategic acquisitions, notably the acquisition of CoverMyMeds for $1.3 billion. However, these investments, combined with ongoing restructuring efforts and a shift in business mix, contributed to margin pressures and higher operating expenses in certain segments, overshadowing the revenue growth. Investors should note the significant impact of the Change Healthcare transaction, which resulted in a substantial loss from equity method investment and a one-time gain related to final adjustments, alongside a continuing trend of share repurchases and a dividend increase.

McKesson Corporation reported third-quarter fiscal year 2017 revenues of $50.1 billion, a 5% increase year-over-year, driven by growth in its Distribution Solutions segment, particularly in North America. Despite revenue growth, gross profit saw a slight decrease of 2% due to weaker pharmaceutical pricing trends and a competitive market, though this was partially offset by acquisitions and LIFO inventory credits. Operating expenses increased by 1% due to acquisitions and ongoing restructuring costs, but also included a significant goodwill impairment charge of $290 million in the Technology Solutions segment. Net income attributable to McKesson Corporation for the quarter was $633 million, a slight decrease from $634 million in the prior year. Diluted earnings per share were $2.85, up from $2.73 in the prior year's comparable quarter. The company is actively managing its capital structure, with a notable increase in share repurchases authorized. Key strategic initiatives include the pending Healthcare Technology Net Asset Exchange with Change Healthcare, expected to close in the first half of calendar year 2017, and the recent acquisition of Rexall Health, further expanding its Canadian retail pharmacy presence. These strategic moves, coupled with ongoing operational adjustments and a focus on managing costs, indicate a dynamic period for McKesson.

McKesson Corporation's Q2 FY17 filing (ending September 30, 2016) reveals a notable shift in financial performance, with revenues growing 2% year-over-year to $49.96 billion, primarily driven by the Distribution Solutions segment. However, net income attributable to McKesson Corporation saw a significant decline of 50% to $307 million, or $1.34 per diluted share, compared to the prior year's $617 million ($2.63 per diluted share). This decline is largely attributable to a substantial $290 million goodwill impairment charge related to the Technology Solutions segment's EIS business and increased operating expenses, partially offset by a cost alignment plan. Strategic initiatives are a key theme, with the proposed formation of a joint venture with Change Healthcare to create a new healthcare IT company, expected to close in H1 2017. Assets and liabilities related to the Core MTS Business to be contributed to this JV were classified as held for sale. Furthermore, McKesson has made several strategic acquisitions in the oncology space (Vantage, Biologics) and in the UK (UDG, Sainsbury) to bolster its Distribution Solutions segment. Despite the net income drop, the company reported strong operating cash flow generation and maintained its commitment to returning capital to shareholders through dividends and an authorized $4 billion share repurchase program.

McKesson Corporation reported a 5% increase in revenue for the first quarter of fiscal year 2017, reaching $49.7 billion, compared to $47.5 billion in the prior year. This growth was primarily driven by the Distribution Solutions segment, bolstered by recent acquisitions and market expansion. While revenue saw a healthy increase, net income attributable to McKesson Corporation decreased by 6% to $542 million ($2.38 per diluted share) from $576 million ($2.45 per diluted share) in the same period last year. This decline was largely due to a significant $113 million after-tax loss from the divestiture of its Brazilian pharmaceutical distribution business. The company announced a significant strategic move: a joint venture with Change Healthcare Holdings, Inc., which will combine a majority of McKesson's Technology Solutions (MTS) business with Change Healthcare's assets. This move is expected to create a new healthcare information technology company, with McKesson retaining a 70% ownership stake. The transaction is anticipated to close in the first half of calendar year 2017, subject to regulatory approvals. This strategic partnership is a key development for McKesson's future growth and focus in the healthcare technology sector.

McKesson Corporation reported strong financial results for the nine months ended December 31, 2015, with revenues increasing by 8% to $144.2 billion and net income attributable to McKesson Corporation growing by 36% to $1.83 billion. This growth was driven by robust performance in its Distribution Solutions segment, particularly in North America, which saw an 12% increase in revenue. The company also demonstrated improved profitability, with income from continuing operations before income taxes rising 27% year-over-year. Operationally, McKesson managed its expenses effectively, with a decrease in operating expenses as a percentage of revenues. The company also returned capital to shareholders through dividends and share repurchases, signaling confidence in its financial stability and future prospects. While facing some international revenue headwinds due to currency fluctuations and specific market challenges, the overall financial health and operational execution remain positive, indicating a solid performance for the period.

McKesson Corporation's (MCK) Q2 fiscal year 2016 report shows robust revenue growth, with a 10% increase year-over-year to $48.8 billion for the quarter and a 10% increase to $96.3 billion for the first six months. This growth was primarily driven by the Distribution Solutions segment, particularly North America pharmaceutical distribution and services, which saw a 16% revenue increase in the quarter. Net income attributable to McKesson Corporation rose significantly by 32% to $617 million for the quarter, resulting in diluted earnings per share of $2.63, up from $1.99 in the prior year. The company continues to expand its operations through strategic acquisitions, announcing agreements to acquire the pharmaceutical distribution business of UDG Healthcare Plc and the pharmacy business of J Sainsbury Plc. These moves are expected to bolster its International pharmaceutical distribution and services within the Distribution Solutions segment. Despite these strategic investments and a challenging pricing environment due to generic drug conversions, McKesson demonstrated strong operational performance and increased profitability, positioning it favorably for continued growth.

McKesson Corporation reported strong financial performance for the quarter ended June 30, 2015, demonstrating significant year-over-year growth in key metrics. Revenues surged by 9% to $47.5 billion, driven primarily by the Distribution Solutions segment, particularly North America pharmaceutical distribution. This top-line growth translated into substantial bottom-line improvement, with Income from Continuing Operations increasing by 43% to $599 million and Net Income Attributable to McKesson Corporation rising by 43% to $576 million. Diluted Earnings Per Share (EPS) also saw a robust increase, growing 42% to $2.45 from $1.72 in the prior year's comparable quarter. This growth was fueled by increased operating profit across segments, strategic business gains such as the sale of the nurse triage business, and the favorable impact of antitrust legal settlements. The company maintained a solid financial position, with a healthy cash balance and effective management of its debt-to-capital ratio.

McKesson Corporation's third quarter and first nine months of fiscal year 2015 reported significant revenue growth, largely driven by the strategic acquisition of Celesio AG in February 2014. Revenues surged by 37% and 36% for the respective periods, with the Distribution Solutions segment being the primary contributor. Despite the revenue increase, investors should note the impact of various charges and expenses, including integration costs for Celesio, LIFO inventory adjustments, and previously disclosed litigation expenses. While net income attributable to McKesson Corporation showed a substantial increase to $472 million ($2.00 per diluted share) for the quarter and $1,344 million ($5.72 per diluted share) for the nine months, this was also influenced by the reclassification of Celesio's noncontrolling interests to redeemable noncontrolling interests, reflecting a significant financial restructuring related to the acquisition. The company affirmed its liquidity position, expecting sufficient cash flow to fund operations. However, potential legal and regulatory challenges, particularly concerning controlled substance distribution, remain a factor to monitor.

McKesson Corporation reported strong revenue growth for the quarter and six months ending September 30, 2014, with a significant portion driven by the acquisition of Celesio AG in February 2014. This strategic move expanded McKesson's global footprint, contributing substantially to revenue and gross profit increases. Despite higher operating expenses, largely due to integration costs and amortization from the Celesio acquisition, the company demonstrated improved profitability from continuing operations. Investors will note the company's continued focus on returning value through dividends, while also managing its debt levels following the acquisition.

McKesson Corporation's (MCK) fiscal first quarter of 2015 (ending June 29, 2014) showed robust revenue growth of 37% year-over-year, reaching $44.1 billion. This significant increase was primarily driven by the recent acquisition of Celesio AG, which contributed $7.6 billion in international pharmaceutical distribution and services revenue and was consolidated into the Distribution Solutions segment. Despite the revenue surge, net income attributable to McKesson Corporation declined by 5% to $403 million, resulting in diluted earnings per share of $1.72, down from $1.83 in the prior year's quarter. The substantial revenue growth is largely attributable to the integration of Celesio, expanding McKesson's global footprint. However, increased operating expenses, including higher amortization and acquisition-related costs stemming from the Celesio acquisition, along with a LIFO-related inventory charge of $98 million, impacted profitability. Investors should note the significant increase in long-term debt ($1.2 billion more than the prior quarter) primarily due to financing the Celesio acquisition, which also led to a rise in interest expense.

McKesson Corporation reported its third quarter fiscal year 2014 results, showing a significant increase in revenues driven by market growth and the acquisition of PSS World Medical. However, net income and diluted earnings per share experienced a substantial decline year-over-year, primarily impacted by increased litigation charges, technology solutions charges, and expenses related to the proposed acquisition of Celesio AG. The company is actively pursuing the acquisition of Celesio AG, which, if successful, is expected to be a transformative event, significantly expanding its international presence. Despite the near-term earnings pressure, McKesson's core business demonstrates continued revenue growth, and the company remains focused on strategic initiatives, including its pending European expansion.

McKesson Corporation reported solid financial results for the second quarter and first six months ended September 30, 2013. The company demonstrated consistent revenue growth, driven primarily by its Distribution Solutions segment. Net income saw a slight increase year-over-year for the quarter and a more significant jump for the six-month period, indicating effective cost management and operational efficiency. Key financial highlights include substantial revenue increases driven by market growth and the PSS World Medical acquisition, alongside improvements in gross profit margin. While facing some litigation charges and LIFO adjustments, the company's core business operations remain robust. McKesson also continues to manage its capital effectively through share repurchases and dividend payments, signaling confidence in its ongoing financial health and commitment to shareholder returns.

McKesson Corporation reported solid financial performance for the quarter ended June 30, 2013, with a 5% increase in total revenues to $32.2 billion compared to the prior year. This growth was driven primarily by the Distribution Solutions segment, which benefited from market expansion, increased drug utilization, price increases, and the recent acquisition of PSS World Medical. The company also saw a significant improvement in gross profit, up 23%, and a notable increase in operating income. Net income rose by 12% to $424 million, translating to a 16% increase in diluted earnings per common share to $1.83. The company demonstrated strong operational cash flow generation of $716 million for the quarter. McKesson also continues its commitment to returning value to shareholders, with a recent increase in its quarterly dividend and ongoing share repurchase programs. While facing ongoing litigation, the company maintains a solid financial position and expects its liquidity sources to be sufficient for its needs.

McKesson Corporation's third-quarter and nine-month results for the period ending December 31, 2012, show modest revenue growth, with revenues increasing by 1% for both the quarter and the first nine months compared to the prior year. Net income for the nine-month period saw a significant 22% increase to $1,079 million, while the third quarter experienced a slight 1% decrease to $298 million. Diluted earnings per share for the nine-month period rose substantially by 28% to $4.49, indicating improved profitability on a year-to-date basis. The company is actively pursuing strategic growth through acquisitions, notably the pending $2.1 billion acquisition of PSS World Medical, Inc., and the recently completed $925 million acquisition of Katz Group's Canadian assets. These moves are expected to bolster the Distribution Solutions segment. McKesson also continues its share repurchase program, demonstrating a commitment to returning value to shareholders.

McKesson Corporation reported solid financial results for the second quarter and first six months of fiscal year 2013. Net income saw a substantial increase, rising by 35% year-over-year for the quarter and 34% for the six-month period, translating to a significant improvement in diluted Earnings Per Share (EPS). This performance was driven by growth in the Distribution Solutions segment and a notable reduction in litigation charges compared to the prior year, which had a substantial impact on profitability. The company also benefited from a gain on a business combination during the first half of the fiscal year. Revenues remained relatively stable, showing a slight decrease of 1% for the quarter but a 1% increase for the six-month period, reflecting a mix of offsetting factors including price deflation in the pharmaceutical market and overall market growth. The company continued its strategic initiatives, including significant share repurchases which contributed positively to EPS. McKesson also made progress in managing its working capital and maintained a strong liquidity position, with sufficient operating cash flow and access to credit facilities to fund its operations and capital requirements. While revenues showed resilience, the company is navigating a dynamic market environment characterized by factors such as generic drug conversions and ongoing legal proceedings, although the impact of these legal matters appears to be moderating compared to the previous year.

McKesson Corporation (MCK) reported strong revenue growth and improved profitability for the quarter ended June 30, 2012. Total revenues increased by 3% year-over-year, driven primarily by the Distribution Solutions segment, which continues to benefit from market growth, increased volumes with existing customers, and new customer acquisitions. The company also saw a significant increase in operating income and net income, largely due to a substantial $81 million gain from acquiring the remaining stake in its corporate headquarters building and continued operational efficiencies. Despite a $16 million charge related to Average Wholesale Price (AWP) litigation, the company's net income rose by 33% and diluted earnings per share (EPS) increased by 40% compared to the prior year. McKesson also continued its commitment to returning capital to shareholders through share repurchases, further boosting EPS. The company's liquidity remains strong, with ample cash and access to credit facilities to support ongoing operations and strategic initiatives.

McKesson Corporation's (MCK) 10-Q filing for the period ending December 31, 2011, demonstrates robust revenue growth, primarily driven by its Distribution Solutions segment. The company reported a significant increase in both quarterly and year-to-date revenues, reflecting market growth and the positive impact of the US Oncology acquisition. Despite facing ongoing litigation charges, particularly related to Average Wholesale Price (AWP) claims, McKesson has shown improved profitability from continuing operations, with diluted earnings per share seeing substantial year-over-year growth. The balance sheet indicates a healthy increase in cash and cash equivalents and total assets, supported by growing inventory and receivables. The company continues to actively manage its capital structure, with substantial share repurchase programs in place. McKesson also provided an update on its European operations with a subsequent event announcing the agreement to acquire certain Canadian assets, signaling continued strategic expansion. Overall, the filing presents a company experiencing top-line growth with improving operational performance, albeit with persistent legal contingencies requiring careful monitoring.

McKesson Corporation's 10-Q filing for the period ending September 30, 2011, showcases solid revenue growth driven primarily by its Distribution Solutions segment, which now includes the recently acquired US Oncology Holdings, Inc. The company reported an increase in revenue for both the quarter and the first six months of the fiscal year, reflecting market growth and strategic acquisitions. While net income saw a slight decrease year-over-year, largely due to a significant increase in litigation charges related to the Average Wholesale Price (AWP) litigation, income from continuing operations demonstrated a positive trend. Despite the impact of AWP litigation charges and an asset impairment charge in the prior year's Technology Solutions segment, the company's financial health appears robust. McKesson maintains a strong balance sheet with increased cash and cash equivalents and a manageable debt-to-capital ratio. The company also continued its commitment to shareholder returns through increased dividends and significant share repurchases. Investors can find reassurance in the company's consistent revenue generation and strategic growth initiatives, though the ongoing legal matters, particularly the AWP litigation, warrant close monitoring.

McKesson Corporation's 10-Q filing for the quarter ended June 29, 2011, reveals a company operating with strong revenue growth, a common theme in the pharmaceutical distribution sector. While specific figures are not detailed in the provided excerpt, the inclusion of condensed consolidated statements of operations, balance sheets, and cash flows indicates a thorough review of the company's financial health and performance. Investors should pay close attention to the Management's Discussion and Analysis (MD&A) section, which would typically elaborate on the drivers behind revenue changes, profitability, and any significant operational developments impacting the quarter. The filing also highlights crucial elements like Legal Proceedings and Risk Factors, which are vital for understanding potential headwinds or uncertainties facing McKesson. For investors, understanding the company's liquidity, debt levels, and overall financial stability, as presented in the balance sheets and cash flow statements, is paramount. The overall tone of a 10-Q filing typically focuses on providing transparency regarding the company's current financial standing and outlook, allowing investors to make informed decisions.

McKesson Corporation reported its third-quarter and nine-month results for the period ending December 31, 2010. For the third quarter, revenues remained stable year-over-year at $28.2 billion, while net income saw a significant decrease of 52% to $155 million, leading to diluted EPS of $0.60. This decline was largely impacted by a substantial $189 million pre-tax charge related to Average Wholesale Price (AWP) litigation, increased acquisition costs for the US Oncology acquisition, and a decrease in demand due to the H1N1 flu virus. For the nine-month period, revenues increased by 1% to $83.2 billion, but net income decreased by 15% to $780 million, with diluted EPS at $2.96. The nine-month results were also affected by AWP litigation charges and an asset impairment charge on capitalized software, though partially offset by a gain from the sale of a subsidiary and an antitrust settlement. The company completed the significant acquisition of US Oncology for approximately $2.1 billion, which expands its specialty pharmaceutical distribution business and adds practice management services.

McKesson Corporation (MCK) reported its financial results for the fiscal second quarter and first six months ended September 30, 2010. The company demonstrated modest revenue growth, with a 1% increase for the quarter and a 2% increase for the six-month period, reaching $27.5 billion and $55.0 billion, respectively. This growth was primarily driven by its Distribution Solutions segment, which constitutes the majority of its revenue. However, income from continuing operations saw a decline, down 15% for the quarter and 6% for the six months, largely due to significant one-time charges including a $72 million asset impairment charge for capitalized software and a $24 million charge for Average Wholesale Price (AWP) litigation. Despite these challenges, net income increased by 9% for the quarter and 6% for the six months, boosted by a $72 million after-tax gain from the sale of its subsidiary, McKesson Asia Pacific Pty Limited. Earnings per diluted share from continuing operations decreased, but total diluted earnings per share saw an increase due to the aforementioned gain on sale and the impact of share repurchases. The company also highlighted its strong liquidity position and continued commitment to returning capital to shareholders through dividends and share repurchases.

McKesson Corporation's (MCK) 10-Q filing for the quarter ending June 29, 2010, indicates a stable operational and financial environment. The company reported no material changes in its exposure to market risks related to interest and foreign currency exchange rates, nor any significant shifts in its disclosure controls, procedures, or internal financial controls. Management has reaffirmed the effectiveness of these controls, providing assurance to investors regarding the reliability of financial reporting. The report also addresses legal proceedings and risk factors, stating no material changes from previously disclosed information in the 2010 Annual Report (10-K). Significant activity during the quarter involved share repurchases, particularly through an Accelerated Share Repurchase (ASR) program which concluded on July 26, 2010. The company repurchased 12.7 million shares for $1 billion during the first quarter, with an additional 1.9 million shares received post-quarter end, bringing the total repurchased under the ASR to 14.6 million shares at an average price of $68.66. This indicates a commitment to returning capital to shareholders and potentially managing its share count. Investors should note that these repurchases do not include shares used for employee stock option exercises or tax withholding.

McKesson Corporation (MCK) reported a profitable third quarter for fiscal year 2010, with net income of $326 million, a significant improvement from a net loss of $20 million in the prior year's quarter. This turnaround was driven by an increase in revenue, up 4% to $28.3 billion, and a substantial increase in operating income. The company's Distribution Solutions segment showed strong performance, benefiting from increased demand related to the flu season and higher margin sales, while the Technology Solutions segment maintained stable revenues. Key factors contributing to the improved financial results include a substantial reduction in operating expenses, largely due to the absence of a significant litigation charge recorded in the prior year's quarter. The company also benefited from a gain on the sale of an equity investment. McKesson's financial position remains solid, with a healthy increase in cash and cash equivalents and a decrease in its debt-to-capital ratio, indicating effective management of financial resources and a positive outlook for the remainder of the fiscal year.

McKesson Corporation's Form 10-Q for the quarter ended September 30, 2009, indicates a period of modest revenue growth and increased profitability, driven by its Distribution Solutions segment. Total revenues rose by 2% year-over-year to $27.1 billion for the quarter, and by 1% to $53.8 billion for the six-month period. Net income saw a slight decrease of 8% to $301 million for the quarter, primarily due to a significant tax benefit recorded in the prior year's quarter. However, for the six-month period, net income increased by 5% to $589 million. Diluted Earnings Per Share (EPS) reflected these trends, decreasing 5% to $1.11 for the quarter but increasing 9% to $2.17 for the six-month period. The company's financial health appears solid, with a substantial increase in cash and cash equivalents to $3.2 billion, bolstered by strong operating cash flow. The company also addressed significant legal matters, including a substantial settlement payment related to AWP litigation and positive developments in other legal proceedings. Management anticipates sufficient liquidity to fund operations and capital expenditures.